Meeting
2023 ASCO Annual Meeting
Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).
Authors
Matthaios Kapiris
King's College London, London, United Kingdom
Matthaios Kapiris , Aida Santaolalla , Sosipatros Bratsos , Sundeep Ghunam , Louisa McDonald , Moe Muhith , Yin Wu , Alexandros Georgiou , Debra Hannah Josephs , Debashis Sarker , Andrew Cope
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2644)
DOI
10.1200/JCO.2023.41.16_suppl.2644
Abstract #
2644
Poster Bd #
486
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).
First Author: John Yohan Rhee
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Annual Meeting
Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.
First Author: Luca Cantini